Fundraising FoxModus Therapeutics
1 known investors
Find your way into Modus Therapeutics
Sign up to see every warm intro you have to Modus Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Modus Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Modus is a Swedish biotechnology company developing sevuparin, a proprietary polysaccharide, as a treatment for conditions with high unmet medical need including sepsis and septic shock, severe systemic inflammation such as severe malaria, and anemia related to chronic inflammation like kidney disease.
Investors · 1
Funding
SEC filings, press & company announcementsSource: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Modus Therapeutics do?
- Modus is a Swedish biotechnology company developing sevuparin, a proprietary polysaccharide, as a treatment for conditions with high unmet medical need including sepsis and septic shock, severe systemic inflammation such as severe malaria, and anemia related to chronic inflammation like kidney disease.
- Who are Modus Therapeutics's investors?
- Modus Therapeutics's investors include HealthCap.